Abstract-Although angiotensin II (Ang II) plays an important role in heart disease associated with pump dysfunction, its direct effects on cardiac pump function remain controversial. We found that after Ang II infusion, the developed pressure and ϩdP/dt max in isolated Langendorff-perfused mouse hearts showed a complex temporal response, with a rapid transient decrease followed by an increase above baseline. Similar time-dependent changes in cell shortening and L-type Ca 2ϩ currents were observed in isolated ventricular myocytes. Previous studies have established that Ang II signaling involves phosphoinositide 3-kinases (PI3K). Dominant-negative inhibition of PI3K␣ in the myocardium selectively eliminated the rapid negative inotropic action of Ang II (inhibited by Ϸ90%), whereas the loss of PI3K␥ had no effect on the response to Ang II. Consistent with a link between PI3K␣ and protein kinase C (PKC), PKC inhibition (with GF 109203X) reduced the negative inotropic effects of Ang II by Ϸ50%. Although PI3K␣ and PKC activities are associated with glycogen synthase kinase-3␤ and NADPH oxidase, genetic ablation of either glycogen synthase kinase-3␤ or p47
A ngiotensin II (Ang II) plays an important role in cardiovascular physiology and pathology. Circulating Ang II levels and the activity of the local cardiac renin-angiotensin system are increased in heart disease, including cardiac hypertrophy 1 and failure. 2 Chronic Ang II stimulation has been linked to cardiac remodeling (characterized by interstitial fibrosis, myocyte hypertrophy and death, and metabolism alterations), 3, 4 which contributes to decreased mechanical function in heart disease. However, the acute actions of Ang II on cardiac function remain unclear and are controversial with positive, [5] [6] [7] [8] negative, 9 or no 10,11 effects on cardiac contractility reported. Moreover, the signaling pathways mediating the inotropic effects of Ang II are not fully clear. The positive inotropic effects of Ang II have been previously linked to protein kinase C (PKC), 8 L-type Ca 2ϩ currents (I Ca,L ), 6 and ␤-Arrestin-2, 8 as well as secondary endothelin-1 release, 7 whereas negative inotropic effects have been associated with PKC 9, 12 and p38 MAPK 9 activities. Ang II has also been shown to activate phosphoinositide 3-kinases (PI3K) in cardiac myocytes 13, 14 and vascular smooth muscle. 15 Because the class IA PI3K, PI3K␣, enhances cardiac contraction strength 16 and I Ca,L 17, 18 while the class IB PI3K, PI3K␥, decreases cardiac contractility, accelerates cAMP degradation, 19, 20 and increases ␤-adrenergic receptor downregulation, 21 we examined the involvement of PI3K␣ and PI3K␥ in mediating the inotropic effects of Ang II in mouse myocardium. Our results show that Ang II has complex effects on mouse cardiac contractility and I Ca,L , and that PI3K␣, but not PI3K␥, is required for the negative inotropic effects of Ang II. These actions of Ang II are independent of glycogen synthase kinase-3␤ (GSK3␤) or NOX2-NADPH oxidase activity.
Mice lacking PI3K␣ activity in the myocardium (dominant-negative [DN]-PI3K␣) 22 and mice lacking PI3K␥ activity (PI3K␥ Ϫ/Ϫ ) 23 or NOX2-NADPH oxidase activity (p47 phoxϪ/Ϫ ) 24 have been described. To generate conditional cardiac-specific GSK3␤ knockout mice, GSK3␤ flox/flox mice 25 were crossed with mice expressing tamoxifen-inducible ␣-myosin MerCreMer. 26 The ␣-myosin MerCreMer/GSK3␤ flox/flox mice (12 weeks old) were treated with tamoxifen citrate (20 mg/kg per day for 4 days), which reduced cardiac GSK3␤ protein levels by Ͼ90%. A total of 90 mice were used in Langendorff studies. In Langendorff studies, hearts were perfused via the aorta with a modified Krebs solution containing the following (in mmol/L): 118 NaCl, 23 NaHCO 3 , 3.2 KCl, 1.2 KH 2 PO 4 , 2.0 CaCl 2 , 1.2 MgSO 4 , 0.5 Na 2 -EDTA, 11 glucose, and 2 Na-pyruvate (free Ca 2ϩ ϭ1.5 mmol/L), which was bubbled with 95% O 2 -5% CO 2 (pHϭ7.40) and kept at 37°C. A balloon was inserted into the left ventricle to record pressure. Single ventricular myocytes were isolated from mouse hearts with collagenase as previously described. 17 In cell shortening studies, myocytes were fieldstimulated at 1 Hz in Tyrode solution (containing 1.2 mmol/L Ca 2ϩ ). 27 I Ca,L were recorded from myocytes with patch-clamp technique in amphotericin B-perforated configuration. Differences between 2 means were assessed using paired or unpaired Student t tests. Differences among multiple means were assessed by 1-way analysis of variance. PϽ0.05 was considered significant. Group data are expressed as meanϮSEM.
Results
The effects of Ang II on cardiac contractility were examined in isolated Langendorff-perfused mouse hearts. For these studies, hearts were initially equilibrated at a constant coronary perfusion pressure of 80 mm Hg and ventricular end-diastolic pressures were set at Ϸ5 mm Hg (online Supplement) to establish baseline function. Figure 1A shows typical left ventricle pressure traces recorded at the indicated times after Ang II (3 nmol/L) infusion. Ang II caused complex temporal changes in pressure development characterized by rapid reductions (PϽ0.01; nϭ4) of the peak rate of left ventricle pressure development (ϩdP/dt max ) by 32.0%Ϯ4.7% below baseline (from 3154Ϯ175 to 2206Ϯ 215 mm Hg/sec) at Ϸ5 minutes after Ang II. After this rapid reduction, ϩdP/dt max increased (PϽ0.01) and peaked at 69.8%Ϯ4.5% above (PϽ0.01; nϭ4) baseline (ie, 5336Ϯ 121 mm Hg/sec) after Ϸ8 minutes of infusion. The ϩdP/dt max declined thereafter to a plateau above (PϽ0.05; nϭ4) baseline. Similar patterns of change (PϽ0.05;nϭ4) in peak pressure (P peak ) and the peak rate of left ventricle pressure decline (ϪdP/dt min ) were also observed with Ang II infusion. As expected from its vasoconstrictor action, Ang II infusion caused a decrease of 46.9%Ϯ4.0% (PϽ0.01; nϭ4) in coronary artery flow rate at Ϸ5 minutes, which returned to baseline levels at Ϸ8 minutes (Supplemental Figure IA available online at http://hyper.ahajournals.org).
It is conceivable that the negative inotropic effects of Ang II were mediated by changes in coronary vascular resistance, possibly leading to metabolic changes or perfusion-related changes in contractility (ie, Gregg's phenomenon). 28 However, when hearts were perfused at a constant coronary flow rate to achieve a perfusion pressure of Ϸ80 mm Hg at baseline, Ang II (3 nmol/L) caused early decrease (12.6%Ϯ2.5%) followed by a late increase (18.9%Ϯ2.3%) in ϩdP/dt max (PϽ0.01; nϭ5) over baseline (Supplemental Figure IB) . Consistent with its vasoconstrictor action, Ang II also caused time-dependent increases (PϽ0.01; nϭ5) in perfusion pressure when perfusion rate was fixed (Supplemental Figure  IB) . Because vascular effects of Ang II could modulate the inotropic actions of Ang II, hearts were pretreated with P1075, a vasodilator that opens plasmalemmal K ATP channels preferentially (by Ϸ20-fold) in vascular smooth muscle compared to myocardium. 29 As expected, pretreatment with P1075 (100 nmol/L), at fixed coronary flows, decreased (PϽ0.01; nϭ4) the perfusion pressure from 79.4Ϯ1.4 to 64.2Ϯ4.5 mm Hg and eliminated the effects of Ang II on coronary perfusion pressure (Supplemental Figure IC) . Consistent with previous reports showing P1075 dosedependently affects cardiac function, 30, 31 P1075 slightly reduced contractility (ie, reduction of 9.4%Ϯ1.5%; PϽ0.01; nϭ4), probably as a result of action potential abbreviation. 32 More importantly, P1075 did not influence the actions of Ang II. Specifically, Ang II (3 nmol/L) infusion in the presence of P1075 still induced (PϽ0.01; nϭ5) a rapid decline of 12.3%Ϯ1.7% in ϩdP/dt max relative to baseline, followed by an increase that peaked at 13.4Ϯ3.1% above (PϽ0.01) baseline at Ϸ10 minutes after Ang II infusion and, thereafter (at 16 minutes after infusion), remained above (PϽ0.05) baseline ( Figure 1B ). In separate experiments using the same conditions, we found that the ϩdP/dt max remained elevated (PϽ0.01; nϭ6) above baseline for 30 minutes after Ang II treatment. Similar temporal changes in P peak (not shown) as well as ϪdP/dt min and the time constant (Tau) for pressure relaxation (Supplemental Figure II available online at http:// hyper.ahajournals.org) were also observed. In all remaining studies, hearts were pretreated with P1075 before Ang II infusion to prevent the effects of Ang II on coronary artery constriction.
To further characterize the inotropic actions of Ang II, we compared the responses of hearts to different concentrations (3, 30 , and 300 nmol/L) of Ang II. As shown in Figure 1B and Supplemental Table I (available online at http://hyper. ahajournals.org), the magnitude of changes in ϩdP/dt max showed little dose-dependence, and a near-maximal response was obtained at 30 nmol/L, consistent with previous studies. 7 It is notable that ϩdP/dt max showed a small, but highly reproducible, increase before the rapid decline phase, whereas the late-phase increases in ϩdP/dt max occurred earlier (PϽ0.05; nϭ5) with higher Ang II levels. These findings suggest that the positive and negative inotropic actions of Ang II involve separate processes with different kinetics. Similar temporal changes were also observed in ϪdP/dt min during Ang II infusion, as summarized in Supplemental Table I .
Although the myocardial effects of Ang II could be mediated by Ang II receptors in nonmyocyte cells of the heart, Ang II also produced biphasic alterations in cell shortening amplitudes of isolated myocytes ( Figure 2 ). Specifically, the percent cell shortening was decreased (PϽ0.01; nϭ13) by Ϸ50% at 5 minutes after Ang II treatment, followed by Ϸ40% increase (PϽ0.05) above control values at 15 minutes. Ang II had no effect (Pϭ0.98; nϭ14) on percent cell shortening in the presence of the type 1 Ang II receptor (AT 1 R) blocker irbersartan (10 mol/L), supporting the conclusion that AT 1 Rs in cardiomyocytes mediate the contractile effects of Ang II ( Figure 2 ).
Previous studies have reported that Ang II can increase cardiac I Ca,L , 33, 34 which are key elements in cardiac excitation-contraction coupling and contraction. To examine if I Ca,L is affected by Ang II in mouse myocardium, we recorded I Ca,L using whole-cell patch-clamp technique with the amphotericin B-perforated configuration, which appears to be necessary to identify the effects of Ang II on I Ca,L . 33, 34 As shown in Figure 3 , Ang II perfusion of isolated ventricular myocytes caused (PϽ0.05; nϭ7) rapid transient Ϸ10% decreases in I Ca,L , followed by Ϸ13% increases over baseline values, suggesting that the negative and positive inotropic effects of Ang II are, at least partially, mediated by alterations in I Ca,L .
We next attempted to determine the signaling pathways involved in the biphasic effects of Ang II on myocardial contractility. It has been shown that Ang II activates G-protein-coupled receptors, which can signal through PI3K. 15, 35 Because PI3K␥ is G ␤␥ -dependent 36 and regulates cardiac contractility, 19, 37 we initially examined the effects of Ang II on mouse hearts lacking PI3K␥ (PI3K␥ Ϫ/Ϫ ). As expected, 37, 38 Supplemental Figure hearts induced (PϽ0.01; nϭ5) an early-phase reduction (13.1%Ϯ3.4%) in ϩdP/dt max , followed by a late-phase increase (27.3%Ϯ6.5%) over baseline levels (Supplemental Figure III) , with similar changes in ϪdP/dt min (not shown).
The relative changes in dP/dt induced by Ang II in PI3K␥
Ϫ/Ϫ hearts were not different (PϾ0.15; nϭ5) from those observed in wild-type littermate hearts (Supplemental Figure III) . Thus, PI3K␥ does not mediate the actions of Ang II on mouse myocardial contractility. Because AT 1 Rs are coupled to Gq protein, which can regulate PI3K␣, 39 we tested the actions of Ang II in hearts with dominant-negative inhibition of PI3K␣ (DN-PI3K␣). DN-PI3K␣ hearts had slightly lower baseline ϩdP/dt max compared to wild-type hearts ( Figure 4A ), consistent with a recent study. 18 More important, Ang II infusion resulted in a modest and insignificant 2.3%Ϯ0.7% decline in ϩdP/dt max in DN-PI3K␣ hearts (Figure 4 ), which was far less (PϽ0.01; nϭ7) than the 19.6%Ϯ1.6% decline seen in wild-type littermate hearts. However, the late-phase increase in ϩdP/dt max was unaffected (Pϭ0.80; nϭ7) by PI3K␣ inhibition ( Figure  4 ). Ang II infusion of DN-PI3K␣ hearts also caused much smaller (PϽ0.01; nϭ7) decreases in ϪdP/dt min (5.7%Ϯ1.1%) compared to wild-type littermates (23.8%Ϯ1.6% decrease) without causing notable differences (Pϭ0.40; nϭ7) in the late-phase increases of ϪdP/dt min (data not shown). These data demonstrate that PI3K␣ plays an important role in the early-phase negative inotropic and lusitropic effects of Ang II in mouse hearts. PKC activity has been recently linked to PI3K␣. 40 In addition, PKC has been shown to be involved in either the negative 9, 12 or the positive 8 inotropic effects of Ang II. Despite these observations, Ang II (30 nmol/L) infusion still caused biphasic changes (PϽ0.01; nϭ7) in ϩdP/dt max in the presence of GF 109203X (1 mol/L; IC 50 ϭ32 nmol/L for PKC inhibition), with a rapid transient 5.7%Ϯ1.1% decline followed by a 12.0%Ϯ3.0% increase above baseline ( Figure  5 ). However, PKC inhibition reduced (PϽ0.05; nϭ7) the early-phase decreases and the late-phase increases in ϩdP/ dt max by Ϸ50% compared to changes caused by Ang II in the absence of PKC inhibition ( Figure 5 ). PKC inhibition also reduced (PϽ0.01; nϭ7) the early-phase decrease in ϪdP/ dt min by Ϸ50% without affecting (Pϭ0.91; nϭ7) the latephase increase in ϪdP/dt min induced by Ang II (not shown). These results suggest that PKC plays a role in the negative and positive inotropic effects of Ang II.
Both PKC 41 and PI3K 42 (particularly PI3K␣) 43 have been shown to regulate GSK3␤, which plays an important role in heart pump function. 44 However, Ang II infusion into hearts with conditional knockout of GSK3␤ induced biphasic changes (PϽ0.05; nϭ5) in ϩdP/dt max (Supplemental Figure  IVA available online at http://hyper.ahajournals.org) that were not different (PϾ0.19, nϭ5) from changes induced by Ang II in wild-type littermate hearts. These data show that GSK3␤ does not play a role in the inotropic effects of Ang II in mouse hearts.
PKC can be activated by reactive oxygen species. 45 The p47 phox -dependent NADPH oxidase (NOX2) is a key enzyme for cardiac generation of reactive oxygen species 46 and can be activated by PI3K. 47 Therefore, we tested whether NOX2 activity is required for the inotropic effects of Ang II by using mice lacking p47 phox (p47 phoxϪ/Ϫ ). Ang II infusion into p47 phoxϪ/Ϫ hearts induced biphasic changes (PϽ0.05; nϭ5) in ϩdP/dt max (Supplemental Figure IVB) that were not different (PϾ0.34; nϭ5) from changes induced by Ang II in wild-type littermate hearts. These data establish that NOX2 is not required for the inotropic effects of Ang II in mouse hearts.
Discussion
Despite Ang II being an important regulator of the cardiovascular system, its direct effects on cardiac contractility are unclear, with positive, [5] [6] [7] [8] 48 negative, 9,12,49 and no 10,11 effects being reported. Our study shows that Ang II produces negative and positive effects on contractility in mouse hearts. Although the transient negative inotropic actions of Ang II in our studies at constant perfusion pressure could arise from compromised myocardial metabolism resulting from reductions in coronary flow, secondary to vasoconstriction, decreased contractility also was observed when coronary flow was kept constant in the absence or presence of P1075 to dilate the coronary arteries. These findings establish that the contractile effects of Ang II on the myocardium are not mediated indirectly by actions of Ang II on coronary blood vessels. Consistent with this conclusion, Ang II treatment of cardiomyocytes induced a transient impairment of cell shortening amplitude that was followed by a brisk increase in single cell contractility, mimicking the pattern seen in Langendorff hearts. These inotropic effects of Ang II were eliminated by AT 1 R-specific blockade in single cardiomyocytes but were unaffected by pretreatment with ␤-adrenergic receptor blockers (propranolol) in isolated hearts (data not shown), establishing that enhanced local norepinephrine release from autonomous nerve terminals 50 by Ang II or receptor cross-talk between AT 1 R and ␤-adrenergic receptor 49 does not contribute to the actions of Ang II.
Taken together, our studies show that Ang II produces complex contractile responses by direct actions on myocardial AT 1 R. This conclusion is consistent with the observation that Ang II altered I Ca,L in mouse ventricular myocytes, with a time course that mirrored precisely the changes in heart contractility. The potential mechanistic link between cardiac contractility and I Ca,L changes is further supported by our results in DN-PI3K␣ hearts as discussed below. However, it is conceivable that Ang II also affects other end-effectors involved in Ca 2ϩ regulation. Support for this possibility is provided by the indices of ventricular relaxation (ϪdP/dt min and the time constant for pressure relaxation, Tau; Supplemental Figure IIB) , which also showed biphasic alterations after Ang II treatment, consistent with possible changes in sarcoplasmic reticulum Ca 2ϩ ATPase activity or myofilament Ca 2ϩ sensitivity. However, the interpretation of these studies is complicated by complex interdependence of the many processes involved in Ca 2ϩ cycling and contractile protein activation/relaxation. Clearly, additional studies will be required to discern the potential role of other functional proteins and processes in transducing the actions of Ang II.
Regardless of the functional mechanisms involved in mediating contractility changes induced by Ang II, we found that the negative inotropic actions of Ang II were largely abolished in DN-PI3K␣ hearts, but not in PI3K␥ Ϫ/Ϫ hearts. The involvement of PI3K␣, but not PI3K␥ (which is G ␤␥ -dependent 36 and a negative regulator of cardiac contractility 19, 37 ), is somewhat surprising because Ang II signals through G-protein-coupled receptors. These findings, together with observations that genetic inhibition of GSK3␤ or NADPH oxidase did not affect the inotropic effects of acute Ang II stimulation, highlight the divergent mechanisms required for the acute vs long-term regulations of contractility by Ang II. 4, 19, 37, 44 Regardless, it is not clear whether PI3K␣ activity is increased or decreased by elevated Ang II levels. It was previously concluded that G␣q protein, which is linked to AT 1 R, inhibits PI3K␣. 39, 51 Thus, because PI3K␣ positively regulates cardiac I Ca,L 17 and contractility, 18 our results are consistent with the conclusion that Ang II mediates its rapid negative inotropic actions on hearts by inhibiting PI3K␣, leading to decreases in cardiac I Ca,L . This is supported by the rapid transient reduction in I Ca,L after Ang II perfusion in our studies. Involvement of I Ca,L in the PI3K␣-dependent negative contractility effects of Ang II is also consistent with our observation that pretreatment of heart with a PKC inhibitor abolished a large fraction of the reductions in cardiac contractility induced by Ang II because PKC activation can inhibit cardiac I Ca,L . 52 In addition to interfering with Ang II-mediated impairment of contractility, PKC inhibition also blocked Ϸ50% of the positive inotropic actions of Ang II. This dual action of PKC is consistent with previous studies showing that PKC activation can have positive 53 or negative 54 inotropic effects on myocardium. Moreover, because loss of the ␣ isoform of PKC (PKC␣) in myocardium enhances contractility and protects against heart failure, 55 our data support the possibility that the rapid negative inotropic actions of Ang II involve PI3K␣-dependent PKC␣ activation, leading to I Ca,L reductions. On the other hand, global PKC inhibition reduces the positive inotropic actions of Ang II, suggesting that Ang II may enhance contraction by activating other PKC isoforms (besides PKC␣) leading to increased I Ca,L as suggested previously. 34, 48 
Perspectives
In contrast to previous studies, our studies establish that Ang II activation of AT 1 R leads to complex temporal decreases and increases in I Ca,L and contractility in "healthy" mouse myocardium, with the decreases requiring PI3K␣ and PKC. The relevance of our studies to larger mammals, including humans wherein elevations in Ang II are linked to decreased contractility in advanced heart disease, 2 is unclear. Nevertheless, it is conceivable that the PI3K␣-dependent and PKCdependent reductions in I Ca,L and contractility, induced by Ang II, may contribute to the impaired function in heart disease. Moreover, these and other potential mechanisms for the effects of Ang II on heart function in mice might also be relevant to humans, even though the relative contribution of various downstream factors and signaling pathways may be modified in large mammals. Further studies will be required to assess whether targeting pathways mediating the negative inotropic actions of Ang II is a valid strategy for treating patients with heart disease. have been described and were bred in our animal facility. GSK3 flox/flox mice were generated as previously described. 5 Mice expressing the tamoxifen-inducible Cre recombinase protein fused to mutated mouse estrogen receptor (Mer) under the cardiac-specific myosin heavy chain promoter (-myosin MerCreMer) 6 were obtained from Jackson Laboratories. The GSK3 flox/flox mice were crossed with -myosin MerCreMer mice. -myosin MerCreMer/GSK3 flox/flox mice (12 weeks of age) were treated with 20 mg/kg tamoxifen citrate (i.p.; Calbiochem) once a day for 4 consecutive days to generate conditional cardiac-specific GSK3β knockout mice (GSK3β cKO). Treated mice were used 5 days later following the final injection of tamoxifen. GSK3β protein levels were reduced by >90% in GSK3β cKO hearts as assessed by western blotting analysis (data not shown). Only littermate mice were used as controls for the studies using DN-PI3Kα, PI3Kγ-/-, p47 phox -/-and GSK3β cKO mice. A total of 90 mice were used in Langendorff studies. The care and use of animals conformed to the standards of the Canadian Council on Animal Care.
Isolated Langendorff heart study
Hearts were extracted from mice after intraperitoneal (IP) heparin injection (10 IU/g body weight) followed 5 min later by IP injection of ketamine (1 mg/g) plus xylazine (0.2 mg/g) and mounted in a Langendorff perfusion system. Hearts were perfused via the aorta with a modified Krebs solution containing (in mmol/L): 118 NaCl, 23 NaHCO 3 , 3.2 KCl, 1.2 KH 2 PO 4 , 2 CaCl 2 , 1.2 MgSO 4 , 0.5 Na 2 -EDTA, 11 glucose, and 2 Na-pyruvate, which was bubbled with 95% O 2 -5% CO 2 (pH=7.40, free Ca 2+ =1.5 mmol/L) and kept at 37 o C. An inflatable water-filled balloon was inserted into the left ventricle (LV) via a small incision in the left atrium for LV pressure measurement (BIOPAC Systems Inc., Goleta, CA).
After mounting, hearts were equilibrated for 20 minutes at a perfusion pressure of 80 mmHg and an end-diastolic pressure of 5-10 mmHg. In studies with wild-type C57BL/6 mice, only hearts with a sinus heart rate of ≥ 300 beats/min and a LV systolic pressure of ≥ 80 mmHg at the end of the equilibration period were included in the studies. In some studies, coronary flow rate was controlled with a peristaltic pump and set to a fixed value, determined by the requirement to achieve a coronary perfusion pressure of 80 mmHg during the equilibration period. In some studies with a constant flow rate, hearts were pretreated (before AngII infusion) with a vasodilator (P1075, 100 nmol/L) after the equilibrium period, which caused a small decrease in both coronary perfusion pressure and baseline +dP/dt max . Heart rate and the rate of LV pressure changes (+dP/dt max and -dP/dt min ), as well as LV relaxation time constant (Tau), 7 were estimated from LV pressure recordings using Acqknowledge program (BIOPAC Systems Inc., Goleta, CA).
1
Angiotensin II (AngII, Sigma-Aldrich, St. Louis, MO) stock solution (1.5 mmol/L) was prepared in Milli-Q water. P1075 (Tocris Bioscience, Ellisville, MO) stock was prepared in ethanol at 10 mmol/L. GF 109203X (Calbiochem, San Diego, CA) stock were prepared in DMSO at 3.3 mmol/L. On the day of experiments, drug stock solutions were diluted in Krebs solution and administered by slow parallel injection into the perfusion line. Final concentrations of vehicles (ethanol and DMSO) in perfusate were ≤ 0.03%. The delay from the start of the drug injection to the arrival of drugs at the heart was 2-3 min.
Ventricular myocyte isolation
As previously described, 8 hearts were isolated and retrogradely perfused for 5 min with nominally Ca 2+ -free Tyrode solution containing (in mmol/L): 136 NaCl, 5.4 KCl, 0.5 Na 2 HPO 4 , 10 HEPES, 1 MgCl 2 , and 10 glucose (pH=7.40 with NaOH). Following perfusion with a Ca 2+ -free Tyrode solution containing collagenase (0.15 mg/ml, Yalkult, Japan) and protease (0.028 mg/ml, type XIV, Sigma) for ~10 min, the left ventricular free wall was dissected, cut into small pieces and gently triturated to release single myocytes. Isolated myocytes were stored in KB solution, containing (in mmol/L): 100 K-glutamate, 10 K-aspartate, 2.5 KCl, 10 KH 2 PO 4 , 2 MgSO 4 , 5 HEPES, 20 glucose, 20 taurine, 5 creatine, 0.5 EGTA, and 0.1% albumin (pH=7.2 with NaOH), and used for study within 8 h of isolation.
Myocyte cell shortening
Cell shortening were measured as previously described. 9 Myoctes were placed in a chamber (volume=0.5mL) on a microscope stage (IX50, Olympus Inc., Center Valley, PA) and bathed in Tyrode's solution as above with 1.2 mmol/L CaCl 2 added. Myocytes were field-stimulated at 1 Hz using square pulses (5 ms × 6 V, S44 Grass Stimulator，Grass Instrument Co., Quincy, MA) during cell length recording with a video edge detector coupled to a high frequency (240 Hz) charge-coupled camera (Crescent Electronics Inc., Sandy, UT) sampled at 1 kHz. Cell shortening was measured in myocytes without treatment or after 5 min and 15 min of AngII treatment. In some studies, myocytes were pretreated with irbersartan (10 μmol/L) for 10 min before AngII treatment. Cell shortening was expressed as percent shortening relative to the resting diastolic length. 
Recording of L-type Ca

Statistics
Differences between two means were assessed using paired or unpaired Student's t-tests. Differences among multiple means were assessed by one-way analysis of variance (ANOVA) and evaluated post hoc by Bonferroni's test. A P value<0.05 was considered significant. Group data are expressed as mean±S.E.M.
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